Investing in Collegium Pharmaceutical, Inc. (COLL)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)11.14-69
Intrinsic value (DCF)10.51-71
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

COLL or Collegium Pharmaceutical Inc. is a publicly traded biopharmaceutical company that focuses on the development and commercialization of innovative treatments for chronic pain and other diseases. It was founded in 2002 and is headquartered in Stoughton, Massachusetts. The company's primary product is Xtampza ER, an extended-release opioid for the management of severe pain. COLL is committed to addressing the opioid epidemic by developing safer and more effective pain management options. In addition to Xtampza ER, the company has a pipeline of potential treatments for other pain-related conditions, including non-opioid therapies. COLL's dedication to scientific research and development has earned them numerous patents and partnerships with prominent pharmaceutical companies. With a team of experienced professionals and a strong emphasis on patient care, COLL continues to make significant strides in the medical field through innovation and compassion.